Champions Oncology (CSBR) Stock Analysis & Winston Score

Champions Oncology is a small biotechnology company that helps researchers study cancer treatments without testing them on patients first. It grows tiny pieces of a patient's actual tumor — called tumor grafts — inside mice, then tests different drugs on those grafts to see which ones work best. Its main customers are pharmaceutical and biotech companies that want to test experimental cancer drugs before running expensive human clinical trials. The company earns money by charging drug developers for these tumor-testing services, making it a fee-for-service research business rather than a traditional drug maker. It operates primarily in the United States and, with a market cap of roughly $100 million, is considered a micro-cap company. Its library of preserved human tumor models gives it a degree of scientific differentiation, but the business is not yet profitable at the operating level. The key risk is its small scale — it must win enough research contracts from larger pharma companies to cover its costs, leaving it vulnerable if drug development spending slows.